Pramod Darvin
Overview
Explore the profile of Pramod Darvin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
1419
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jayalakshmi J, Thomas T, N S S, N S S, Rajani C, K M L, et al.
Anat Histol Embryol
. 2024 May;
53(3):e13045.
PMID: 38735038
This work extensively studied the vasculature of mice mammary fat pads (BALB/c and C57BL/6) with special reference to haematogenous drainage routes. Mammary fat pads were five pairs (first cervical, second...
2.
Jeethy Ram T, Lekshmi A, Darvin P, Rajappan P, Krishna K, Anoop T, et al.
Tumour Biol
. 2023 Aug;
45(1):31-54.
PMID: 37574746
Background: Lack of druggable targets and complex expression heterogeneity of known targets is common among TNBC subtypes. An enhanced expression of galectin-3 in TNBCs has already been documented. We have...
3.
Jancy S, Lupitha S, Chandrasekharan A, Varadarajan S, Nelson-Sathi S, Prasad R, et al.
Biol Proced Online
. 2023 Jul;
25(1):22.
PMID: 37495994
Background: The entry of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) into the host cell is mediated through the binding of the SARS-CoV-2 Spike protein via the receptor binding domain...
4.
Darvin P, Sasidharan Nair V
Front Oncol
. 2023 Mar;
13:1155774.
PMID: 36998468
No abstract available.
5.
Jerath G, Darvin P, Christian Y, Trivedi V, Santhosh Kumar T, Ramakrishnan V
Mol Pharm
. 2022 Jul;
19(8):2877-2887.
PMID: 35839086
The utilization of peptide-based drug delivery systems has been suboptimal due to their poor proteolytic susceptibility, poor cell permeability, and limited tumor homing capabilities. Earlier attempts in using d-enantiomers in...
6.
Lupitha S, Darvin P, Chandrasekharan A, Varadarajan S, Divakaran S, Easwaran S, et al.
Antib Ther
. 2022 Apr;
5(2):100-110.
PMID: 35437514
Quantitative determination of neutralizing antibodies against Severe Acute Respiratory Syndrome Corona Virus-2 (SARS-CoV-2) is paramount in immunodiagnostics, vaccine efficacy testing, and immune response profiling among the vaccinated population. Cost-effective, rapid,...
7.
Varadarajan S, Mathew K, Chandrasekharan A, Lupitha S, Lekshmi A, Mini M, et al.
J Cell Biochem
. 2022 Feb;
123(4):782-797.
PMID: 35106828
Cancer cells grown as 3D-structures are better models for mimicking in vivo conditions than the 2D-culture systems employable in drug discovery applications. Cell cycle and cell death are important determinants...
8.
Darvin P, Chandrasekharan A, Varadarajan S, Chandrasekhar L, Maliakkal R, S M J, et al.
Photodiagnosis Photodyn Ther
. 2020 Jul;
31:101921.
PMID: 32679191
Background: Photodynamic therapy (PDT) is a successful cancer treatment modality. In vitro, in vivo, and clinical studies with different photosensitizers reveal diverging cell fates, including apoptosis, necrosis, autophagy, and non-specific...
9.
Darvin P, Sasidharan Nair V, Elkord E
J Oncol
. 2019 Mar;
2019:3958908.
PMID: 30915120
Tumor progression through immune evasion is a major challenge in cancer therapy. Recent studies revealed that enhanced PD-L1 expression in cancer stem cells is linked to immune evasion. Understanding the...
10.
Darvin P, Toor S, Sasidharan Nair V, Elkord E
Exp Mol Med
. 2018 Dec;
50(12):1-11.
PMID: 30546008
Cancer growth and progression are associated with immune suppression. Cancer cells have the ability to activate different immune checkpoint pathways that harbor immunosuppressive functions. Monoclonal antibodies that target immune checkpoints...